189 related articles for article (PubMed ID: 1521037)
21. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Pérez-Otaño I; Oset C; Luquin MR; Herrero MT; Obeso JA; Del Río J
Neurosci Lett; 1994 Jul; 175(1-2):121-5. PubMed ID: 7970192
[TBL] [Abstract][Full Text] [Related]
22. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
Hadjiconstantinou M; Mariani AP; Neff NH
Brain Res; 1989 Apr; 484(1-2):297-303. PubMed ID: 2565752
[TBL] [Abstract][Full Text] [Related]
23. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
Gerhardt GA; Cass WA; Huettl P; Brock S; Zhang Z; Gash DM
Brain Res; 1999 Jan; 817(1-2):163-71. PubMed ID: 9889359
[TBL] [Abstract][Full Text] [Related]
24. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate.
Choi JY; Park CS; Kim DJ; Cho MH; Jin BK; Pie JE; Chung WG
Neurotoxicology; 2002 Sep; 23(3):367-74. PubMed ID: 12387363
[TBL] [Abstract][Full Text] [Related]
25. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
Sirinathsinghji DJ; Heavens RP; McBride CS
Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784
[TBL] [Abstract][Full Text] [Related]
26. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
[TBL] [Abstract][Full Text] [Related]
27. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
[TBL] [Abstract][Full Text] [Related]
28. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Ferger B; Teismann P; Earl CD; Kuschinsky K; Oertel WH
Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):256-61. PubMed ID: 10543426
[TBL] [Abstract][Full Text] [Related]
29. Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice.
Gao ZG; Cui WY; Zhang HT; Liu CG
Pharmacol Res; 1998 Aug; 38(2):101-6. PubMed ID: 9721596
[TBL] [Abstract][Full Text] [Related]
30. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
31. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice.
Boeckler F; Leng A; Mura A; Bettinetti L; Feldon J; Gmeiner P; Ferger B
Biochem Pharmacol; 2003 Sep; 66(6):1025-32. PubMed ID: 12963489
[TBL] [Abstract][Full Text] [Related]
33. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.
Irwin I; DeLanney LE; Forno LS; Finnegan KT; Di Monte DA; Langston JW
Brain Res; 1990 Oct; 531(1-2):242-52. PubMed ID: 1981162
[TBL] [Abstract][Full Text] [Related]
34. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
36. Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter.
Clarke PB; Reuben M
Br J Pharmacol; 1995 Jan; 114(2):315-22. PubMed ID: 7881731
[TBL] [Abstract][Full Text] [Related]
37. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
Przedborski S; Kostic V; Jackson-Lewis V; Naini AB; Simonetti S; Fahn S; Carlson E; Epstein CJ; Cadet JL
J Neurosci; 1992 May; 12(5):1658-67. PubMed ID: 1578260
[TBL] [Abstract][Full Text] [Related]
38. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
Bradbury AJ; Costall B; Domeney AM; Testa B; Jenner PG; Marsden CD; Naylor RJ
Neurosci Lett; 1985 Oct; 61(1-2):121-6. PubMed ID: 2417166
[TBL] [Abstract][Full Text] [Related]
39. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
Morgan WW; Nelson JF
Brain Res; 2001 Dec; 921(1-2):115-21. PubMed ID: 11720717
[TBL] [Abstract][Full Text] [Related]
40. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
